Assi Hussein A, Padda Sukhmani K
Division of Hematology/Oncology, Department of Medicine, Stephenson Cancer Center, University of Oklahoma Health Sciences Center, Oklahoma City, OK, United States.
Division of Medical Oncology, Department of Medicine, Stanford Cancer Institute, Stanford University School of Medicine, 875 Blake Wilbur Drive, Stanford, CA 94305, United States.
Cancer Treat Res Commun. 2020;23:100167. doi: 10.1016/j.ctarc.2020.100167. Epub 2020 Jan 16.
Neuroendocrine tumors of the lung are a diverse group of diseases with distinct pathological, molecular, and clinical characteristics. The most recent World Health Organization (WHO) classification identifies two types of high-grade neuroendocrine carcinomas of the lung: small cell lung carcinoma (SCLC), and the less common large cell neuroendocrine carcinoma of the lung (LCNEC). Systemic treatments for these aggressive tumors have largely remained unchanged for years. With the advancement in genomic sequencing and identification of novel targetable pathways over the last decade, a myriad of therapeutic options have emerged, addressing unmet needs for this patient population. In this review, we summarize the latest advances in the management of SCLC and LCNEC, and discuss promising endeavors in development.
肺神经内分泌肿瘤是一组具有不同病理、分子和临床特征的疾病。世界卫生组织（WHO）的最新分类确定了两种类型的肺高级别神经内分泌癌：小细胞肺癌（SCLC）和较罕见的肺大细胞神经内分泌癌（LCNEC）。多年来，针对这些侵袭性肿瘤的全身治疗方法基本没有变化。随着过去十年基因组测序技术的进步以及新的可靶向通路的发现，出现了大量治疗选择，满足了这一患者群体未被满足的需求。在本综述中，我们总结了SCLC和LCNEC治疗的最新进展，并讨论了正在研发的有前景的研究方向。
